Standard BioTools Inc. $LAB is Mak Capital One LLC’s 6th Largest Position

Mak Capital One LLC boosted its holdings in Standard BioTools Inc. (NASDAQ:LAB) by 184.6% in the third quarter, HoldingsChannel.com reports. The firm owned 15,931,806 shares of the company’s stock after buying an additional 10,334,384 shares during the quarter. Standard BioTools comprises about 3.2% of Mak Capital One LLC’s investment portfolio, making the stock its 6th largest holding. Mak Capital One LLC’s holdings in Standard BioTools were worth $20,711,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its position in shares of Standard BioTools by 862.2% during the 1st quarter. AQR Capital Management LLC now owns 482,912 shares of the company’s stock worth $522,000 after buying an additional 432,725 shares during the last quarter. Savant Capital LLC raised its stake in Standard BioTools by 199.3% during the 2nd quarter. Savant Capital LLC now owns 56,957 shares of the company’s stock worth $68,000 after acquiring an additional 37,926 shares in the last quarter. Geode Capital Management LLC lifted its position in Standard BioTools by 3.3% in the second quarter. Geode Capital Management LLC now owns 7,441,134 shares of the company’s stock valued at $8,931,000 after acquiring an additional 235,677 shares during the last quarter. Creative Planning lifted its position in Standard BioTools by 56.6% in the second quarter. Creative Planning now owns 61,102 shares of the company’s stock valued at $73,000 after acquiring an additional 22,082 shares during the last quarter. Finally, Intech Investment Management LLC boosted its stake in Standard BioTools by 6.1% in the second quarter. Intech Investment Management LLC now owns 149,018 shares of the company’s stock valued at $179,000 after acquiring an additional 8,519 shares in the last quarter. 53.74% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have issued reports on LAB. Wall Street Zen lowered Standard BioTools from a “hold” rating to a “sell” rating in a report on Sunday, March 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Standard BioTools in a research report on Thursday, January 22nd. Finally, Zacks Research upgraded Standard BioTools to a “hold” rating in a research note on Thursday, December 11th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $1.35.

Standard BioTools Price Performance

LAB stock opened at $0.96 on Tuesday. The company has a market cap of $367.26 million, a price-to-earnings ratio of -4.77 and a beta of 1.36. The company has a fifty day moving average price of $1.27 and a 200 day moving average price of $1.31. Standard BioTools Inc. has a 12 month low of $0.92 and a 12 month high of $1.72.

Standard BioTools (NASDAQ:LAB) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.08. The company had revenue of $23.80 million for the quarter, compared to the consensus estimate of $18.50 million. Standard BioTools had a negative net margin of 59.39% and a negative return on equity of 11.20%. As a group, analysts anticipate that Standard BioTools Inc. will post -0.29 earnings per share for the current year.

About Standard BioTools

Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.